ICU Medical (ICUI) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $589.1M, up 6.5% year-over-year, with gross profit rising to $204.9M and adjusted EBITDA at $94.8M.

• Net loss for Q3 2024 was $(33.0)M, compared to net income of $7.2M in Q3 2023; adjusted EPS was $1.59.

• Announced a strategic joint venture with Otsuka for IV solutions, deconsolidating ~$350M revenue and ~$25M adjusted EBITDA, with a $200M upfront payment for debt paydown.

• Free cash flow for Q3 was $16.2M, with cash and equivalents at $312.5M at quarter-end.

• Restructuring, strategic transaction, and integration expenses rose to $16.8M in Q3, mainly related to Smiths Medical integration.

Financial highlights

• Q3 2024 revenue: $589.1M (+6.5% YoY); adjusted EBITDA: $94.8M; adjusted EPS: $1.59.

• Gross margin improved to 34.8% in Q3 2024, with adjusted gross margin at 37%.

• SG&A expenses: $162.7M in Q3 2024; R&D expenses: $21.0M.

• Free cash flow for Q3: $16.2M; year-to-date: $109.2M.

• Cash and cash equivalents at quarter-end: $312.5M; debt: $1.6B.

Outlook and guidance

• Adjusted EBITDA guidance raised to $355M–$365M; adjusted EPS guidance increased to $5.40–$5.70.

• FY 2024 GAAP net loss guidance widened to $(130)M–$(122)M; diluted loss per share: $(5.28)–$(4.98).

• Q4 gross margin expected in the 36–37% range, with higher IV solutions mix and FX headwinds.

• Transaction with Otsuka expected to be EPS neutral in 2025.

• Capital expenditures for 2024 estimated at $80–90M.